https://scholars.lib.ntu.edu.tw/handle/123456789/495102
標題: | EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment | 作者: | Huang C.-L. CHIH-HSIN YANG KUN-HUEI YEH Hu F.-C. KUAN-YU CHEN JIN-YUAN SHIH ZHONG-ZHE LIN CHONG-JEN YU ANN-LII CHENG PAN-CHYR YANG |
公開日期: | 2009 | 卷: | 64 | 期: | 3 | 起(迄)頁: | 346-351 | 來源出版物: | Lung Cancer | 摘要: | Background: Skin rash is the most common toxicity of epidermal growth factor receptor (EGFR)-targeted therapy. This study investigated the clinical and genetic factors associated with this skin rash. Methods: Fifty-two non-small cell lung cancer patients enrolled in a clinical trial of first-line gefitinib treatment were genotyped for EGFR intron 1 CA repeat ([CA]n) polymorphism and single nucleotide polymorphisms at G-216T, C-191A, and R521K. The severity of skin rash was correlated with the genotypic and clinicopathological features. Results: Seventeen patients (32.7%) developed grade 2-3 skin rashes within 4 weeks of treatment (early G2/3 rash). In the multivariate logistic regression analysis, only the [CA]n genotype was correlated with early G2/3 rash; and this relationship was modified by age. Early G2/3 rash developed in 21% of patients with homozygous long allele (19-22 repeats, L) genotype, 31% with heterozygous short allele (15-18 repeats, S)/L genotype, and 71% with S/S genotype, respectively. The estimated logarithm of odds ratio (ln OR) for early G2/3 rash, as compared to S/S genotype, for S/L genotype was -0.038 multiplied by age (P = 0.011); and the ln OR for L/L genotype was -0.050 multiplied by age (P = 0.004). Early G2/3 rash was correlated with tumor response in the multiple logistic regression analysis (P = 0.027). However, the [CA]n genotype was not significantly correlated with tumor response (P = 0.35). Conclusions: EGFR [CA]n genotype appears to be a useful predictive marker of the development of skin rashes with gefitinib treatment. ? 2008 Elsevier Ireland Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349206986&doi=10.1016%2fj.lungcan.2008.09.009&partnerID=40&md5=67a46a95619c26205ce95b40d51cce40 https://scholars.lib.ntu.edu.tw/handle/123456789/495102 |
ISSN: | 0169-5002 | DOI: | 10.1016/j.lungcan.2008.09.009 | SDG/關鍵字: | dinucleotide; epidermal growth factor receptor; gefitinib; adult; aged; allele; article; clinical feature; clinical study; clinical trial; controlled study; correlation analysis; disease severity; dry skin; female; genotype; heredity; homozygote; human; human tissue; intron; lung adenocarcinoma; major clinical study; male; multivariate logistic regression analysis; paronychia; pathology; phase 2 clinical trial; prediction; priority journal; rash; risk; single nucleotide polymorphism; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Exanthema; Female; Genes, erbB-1; Humans; Inteins; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Quinazolines; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。